UY29451A1 - Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida - Google Patents

Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida

Info

Publication number
UY29451A1
UY29451A1 UY29451A UY29451A UY29451A1 UY 29451 A1 UY29451 A1 UY 29451A1 UY 29451 A UY29451 A UY 29451A UY 29451 A UY29451 A UY 29451A UY 29451 A1 UY29451 A1 UY 29451A1
Authority
UY
Uruguay
Prior art keywords
disustituted
tiazolo
pirimidin
ona
diseases
Prior art date
Application number
UY29451A
Other languages
English (en)
Spanish (es)
Inventor
Nordvall Gunnar
Ray Colin
Rein Tobias
Sohn Daniel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29451A1 publication Critical patent/UY29451A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY29451A 2005-04-06 2006-04-04 Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida UY29451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500768 2005-04-06

Publications (1)

Publication Number Publication Date
UY29451A1 true UY29451A1 (es) 2006-11-30

Family

ID=37073738

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29451A UY29451A1 (es) 2005-04-06 2006-04-04 Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida

Country Status (18)

Country Link
US (1) US8088780B2 (OSRAM)
EP (1) EP1869055A1 (OSRAM)
JP (1) JP2008535834A (OSRAM)
KR (1) KR20080004484A (OSRAM)
CN (1) CN101193898B (OSRAM)
AR (1) AR053347A1 (OSRAM)
AU (1) AU2006231835B8 (OSRAM)
BR (1) BRPI0609736A2 (OSRAM)
CA (1) CA2604016A1 (OSRAM)
IL (1) IL185913A0 (OSRAM)
MX (1) MX2007012067A (OSRAM)
NO (1) NO20075610L (OSRAM)
NZ (1) NZ561462A (OSRAM)
RU (1) RU2411245C9 (OSRAM)
TW (1) TW200720279A (OSRAM)
UY (1) UY29451A1 (OSRAM)
WO (1) WO2006107257A1 (OSRAM)
ZA (1) ZA200708182B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
CA2714436C (en) 2008-03-07 2017-06-27 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
LT2254869T (lt) 2008-03-07 2017-08-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
JP5509102B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
EP2432776B1 (en) 2009-05-21 2019-09-11 Universite Laval Methyl sulfanyl pyrimidines useful as antiinflammatories, analgesics, and antiepileptics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
JO3082B1 (ar) * 2011-09-13 2017-03-15 Eisai R&D Man Co Ltd مشتق بيروليدين-3- يل حمض خليك
AU2014231863B2 (en) * 2013-03-12 2017-07-27 Eisai R&D Management Co., Ltd. Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
WO2014142086A1 (ja) * 2013-03-13 2014-09-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン－３－イル酢酸誘導体およびピペリジン－３－イル酢酸誘導体
EP3294745B1 (en) * 2015-05-08 2020-01-01 H. Hoffnabb-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
KR20250086780A (ko) 2022-10-19 2025-06-13 아스트라제네카 아베 Cx3cr1 조절제로서의 2,4,6-삼중치환된 1,3,5-트리아진
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (OSRAM) 1955-01-03
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
ATE214704T1 (de) * 1997-07-18 2002-04-15 Hoffmann La Roche 5h-thiazolo(3,2-a)pyrimidinderivate
WO1999051608A1 (en) 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
US6670446B1 (en) 1998-05-01 2003-12-30 Eli Lilly And Company N1 modified glycopeptides
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60101372T2 (de) 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
JP2007507494A (ja) * 2003-10-07 2007-03-29 アストラゼネカ・アクチエボラーグ ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Also Published As

Publication number Publication date
NZ561462A (en) 2010-12-24
US20090124637A1 (en) 2009-05-14
EP1869055A1 (en) 2007-12-26
AU2006231835B8 (en) 2010-10-14
AR053347A1 (es) 2007-05-02
AU2006231835A1 (en) 2006-10-12
BRPI0609736A2 (pt) 2011-10-18
RU2411245C9 (ru) 2011-05-27
KR20080004484A (ko) 2008-01-09
RU2007140552A (ru) 2009-05-20
IL185913A0 (en) 2008-01-06
JP2008535834A (ja) 2008-09-04
AU2006231835B2 (en) 2010-09-30
NO20075610L (no) 2008-01-07
US8088780B2 (en) 2012-01-03
CN101193898B (zh) 2010-12-01
TW200720279A (en) 2007-06-01
CN101193898A (zh) 2008-06-04
ZA200708182B (en) 2008-11-26
MX2007012067A (es) 2007-12-04
CA2604016A1 (en) 2006-10-12
WO2006107257A1 (en) 2006-10-12
RU2411245C2 (ru) 2011-02-10

Similar Documents

Publication Publication Date Title
UY29451A1 (es) Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida
UY31734A (es) Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona
CY1111316T1 (el) Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης
NI200900204A (es) COMPUESTOS AMINO-HETEROCÍCLICOS. Caso: PC 33468A
ATE424402T1 (de) Imidazopyridinverbindungen
CR10682A (es) Compuestos de tiazol pirazolopirimidina
DOP2011000135A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
CL2008002351A1 (es) Compuestos derivados de 6-triazolopiridazina-sulfanil benzotiazol y bencimidazol; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del cancer.
CO6501188A2 (es) Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1
CL2012000981A1 (es) Compuestos derivados de 5-etinil-2-[(3-fenil-1h-pirazolo[3.4-d]pirimidin-1-il)metil]quinazolin-4(3h)-ona, inhibidores de fosfoinositida 3-quinasa compuestos intermediarios; sin accion farmacologica; composicion farmaceutica; utiles en el tratamiento de epoc, asma fibrosis quistica y pulmonar, sarcoidosis, entre otras.
CR10387A (es) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
CY1110711T1 (el) Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3
UY30612A1 (es) Derivados 5,7 disustituidos de la [1,3]tiazolo[4,5,d]pirimidin-2(3h)-ona, proceso de preparacion y aplicaciones
WO2008039139A8 (en) Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
PA8628901A1 (es) Derivados de 4-alquil-y 4-alcanoil-piperidina sustituidos y su uso como antagonistas de neuroquininas
UY30880A1 (es) 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
UY29398A1 (es) Derivados de quinazolinas, sussales farmacéuticamente aceptables, composiciones que los contienen, procedimientos de preparación y aplicacións.
UY30699A1 (es) Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UA95811C2 (en) 5,7-disubstituted [1,3]thiazolo [4,5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
UA95966C2 (en) 5,7-disubstituted[1,3]thiazolo[4,5]pyrimidin-2(3h)-amine derivatives and their use in therapy
UY28515A1 (es) Derivados de quinazolina
DOP2009000047A (es) Tiazol pirazolopirimidinas como antagonistas del receptor crf1

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120426